The Outcome of Treatment With Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke

Background: Thrombolytic therapy is the recommended treatment of acute ischemic stroke. It crucial to evaluate results with recombinant Tissue Plasminogen Activator (r-TPA) in patients Objectives: This study aimed outcomes r-TPA stroke a referral center Iran. Materials & Methods: In this retrospective study, 87 symptoms were examined. They referred Gilan Province, Iran, from June 2016 April 2020 and received (0.9 mg/kg). Demographic information, time interval between onset administration, complications, National Institutes Health Stroke Scale (NIHSS) upon arrival discharge death extracted their hospital files. The paired t-test, independent Pearson correlation test used compare variables using IBM SPSS for Windows version 20.0 (IBM Corp., Armonk, NY, USA). Results: Mean±SD NIHSS reduced 14.7±6.4 8.9±7.6 (P<0.001). most common complication was Intracerebral Hemorrhage (ICH) (12.6%). mortality rate 23%. ICH occurred among 40% (n=8) those who expired, 4.47% (n=3) them survived, difference significant Conclusion: recovery administration acceptable. Mortality occurrence rates higher than other non-Iranian studies. seems that we should change case selection criteria prescription dose achieve better TPA.